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Recent advances reveal that metabolic reprogramming is required for adequate antiviral
responses of dendritic cells (DCs) that possess the capacity to initiate innate and adaptive
immune responses. Several reports indicate that Toll-like receptor (TLR) stimulation
of DCs is accompanied by a rapid induction of glycolysis; however, the metabolic
requirements of retinoic-acid inducible gene I (RIG-I)-like receptor (RLR) activation have
not defined either in conventional DCs (cDCs) or in plasmacytoid DCs (pDCs) that are
the major producers of type I interferons (IFN) upon viral infections. To sense viruses
and trigger an early type I IFN response, pDCs rely on endosomal TLRs, whereas cDCs
employ cytosolic RIG-I, which is constitutively present in their cytoplasm. We previously
found that RIG-I is upregulated in pDCs upon endosomal TLR activation and contributes
to the late phase of type I IFN responses. Here we report that TLR9-driven activation
of human pDCs leads to a metabolic transition to glycolysis supporting the production
of type I IFNs, whereas RIG-I-mediated antiviral responses of pDCs do not require
glycolysis and rather rely on oxidative phosphorylation (OXPHOS) activity. In particular,
TLR9-activated pDCs show increased extracellular acidification rate (ECAR), lactate
production, and upregulation of key glycolytic genes indicating an elevation in glycolytic
flux. Furthermore, administration of 2-deoxy-D-glucose (2-DG), an inhibitor of glycolysis,
significantly impairs the TLR9-induced secretion of type I IFNs by human pDCs. In
contrast, RIG-I stimulation of pDCs does not result in any alterations of ECAR, and type I
IFN production is not inhibited but rather promoted by 2-DG treatment. Moreover, pDCs
activated via TLR9 but not RIG-I in the presence of 2-DG are impaired in their capacity to
prime allogeneic naïve CD8+ T cell proliferation. Interestingly, human monocyte-derived
DCs (moDC) triggered via RIG-I show a commitment to glycolysis to promote type I IFN
production and T cell priming in contrast to pDCs. Our findings reveal for the first time, that
pDCs display a unique metabolic profile; TLR9-driven but not RIG-I-mediated activation
of pDCs requires glycolytic reprogramming. Nevertheless, the metabolic signature of
RIG-I-stimulated moDCs is characterized by glycolysis suggesting that RIG-I-induced
metabolic alterations are rather cell type-specific and not receptor-specific.
Keywords: plasmacytoid dendritic cell, dendritic cell, metabolic reprogramming, glycolysis, RIG-I, TLR, type I
interferon, antiviral response
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INTRODUCTION
DCs as part of the innate immune system constitute the first
line of defense against viral infections playing a crucial role in
both the recognition of foreign nucleic acids and subsequent
triggering of antiviral responses (1). The innate immune response
to viral infections is initiated when germ line-encoded pattern
recognition receptors (PRRs) recognize specific viral molecular
patterns (2). Upon binding to viral components, the main viral
sensors such as endosomal TLRs and cytosolic RLRs induce
signaling cascades that stimulate the rapid expression of genes
encoding antiviral products like type I IFNs (3).
Plasmacytoid DCs are a rare subtype of DCs that are
specialized in producing large amounts of type I IFNs in
response to viruses (4). Unlike cDCs, pDCs are resistant to
most viral infections and require a direct physical contact
with infected cells or an uptake of virus-derived components
released by them to successfully mount an antiviral state (5, 6).
Plasmacytoid DCs are known to rely mainly on the endosomal
TLR7 and TLR9 receptors to detect viral nucleic acids, whereas
cDCs preferentially use cytosolic RLRs to recognize replicating
viral RNA intermediates (2, 7). Intriguingly, recent findings
including ours suggest that besides the TLR-mediated sensing
of viral nucleic acids, RLRs are also involved in virus-triggered
pDCs activation (8–11). We have recently found that RIG-I, a
cytoplasmic sensors of viral RNA, is absent from quiescent pDCs
but can be greatly upregulated upon endosomal TLR stimulation
(8). Further we have proposed a model where endosomal TLRs
mediate the first wave of type I IFN production while RIG-I
contributes to the late phase of type I IFN responses in pDCs (8).
A growing body of evidence indicates that the activation of
DCs does not only trigger changes in the expression of genes
associated with immune responses but also induce metabolic
reprogramming, which is important to meet the energetic needs
of DC activation [reviewed in (12)]. Interestingly, to ensure
optimal environment for replication, viruses also modulate host
cellular metabolism inducing specific host metabolic pathways
by distinct mechanisms (13). Various families of viruses have
shown to alter core cellular metabolic pathways: most viruses
induce glycolysis, whereas others induce fatty acid synthesis as
well as glutaminolysis (14). In addition it has been recognized
that there is a crosstalk between the immune system and
cellular metabolism; immune cells can shift their metabolism
in response to distinct microenvironmental stimuli e.g., viral
infections (14). Recent evidence indicates that activation of DCs
andmacrophages is accompanied by rapid induction of glycolysis
that provides adequate energy for activation and cytokine
production [reviewed in (15)]. Moreover, in cDCs a range of
TLR agonists has been found to induce a metabolic switch from
Abbreviations: 2-DG, 2-deoxy-D-glucose; CCCP, carbonyl cyanide m-
chlorophenyl hydrazone; cDC, conventional DC; DC, dendritic cell; ECAR,
extracellular acidification rate; HIF1A, hypoxia-inducible factor 1-alpha; HK2,
hexokinase 2; IFN, interferon; LDHA, lactate dehydrogenase A; moDC, monocyte-
derived DC; mtROS, mitochondrial reactive oxygen species; OCR, oxygen
consumption rate; OXPHOS, oxidative phosphorylation; pDC, plasmacytoid DC;
RIG-I, retinoic-acid inducible gene I; RLR, RIG-I-like receptors; TLR, Toll-like
receptors.
OXPHOS to glycolysis which supports fatty acid synthesis that
is required for DC activation (16, 17). Regarding the metabolic
signature of activated pDCs only few studies are available, that all
focus on endosomal TLR-driven metabolic alterations of pDCs
(18–20). In particular, human pDCs show enhanced glycolytic
activity upon stimulation with TLR7 specific respiratory viruses
such as Flu and RV-16 virus and the synthetic TLR7 agonist
gardiquimod (20). In contrast, activation ofmouse pDCs through
endosomal TLR9 resulted in increased OXPHOS and fatty
acid oxidation (18). Furthermore, the authors demonstrated
that the metabolic transition regulated through an autocrine
type I IFN signaling loop is also characterized by changes in
lipid metabolism that partially depends on the nuclear receptor
peroxisome proliferator-activated receptor alpha (PPARα) in
murine pDCs (18). All these findings imply that the activation-
induced metabolic reprogramming of DCs might depend on the
origin and source of the cells, the type of receptors as well as the
activation signals.
As far as we know there are no data in the literature
concerning the metabolic adaptation of DCs in response to RLR
stimulation. Hence the primary goal of the present study is to
address the link between cellular metabolism and RLR-mediated
signal transduction in human DCs. In particular, we sought to
explore the metabolic signature of RIG-I-activated human pDCs.
Furthermore, we aimed to compare the metabolic requirements
of RIG-I stimulated human pDCs andmoDCs displaying distinct
viral sensing machinery and different cytosolic RIG-I expression
profile.
MATERIALS AND METHODS
Cell Line
The human plasmacytoid dendritic cell line GEN2.2 (21)
(provided by Dr. Joel Plumas and Dr. Laurence Chaperot,
Research and Development Laboratory, French Blood Bank
Rhône-Alpes, Grenoble, France) was used in our experiments,
which is deposited with the CNCM (French National Collection
of Microorganism Cultures) under the number CNCMI-2938.
GEN2.2 cells were grown on a layer of mitomycin C (Sigma-
Aldrich, St. Louis, MO, USA)-treated murine MS5 feeder cells
(Cat. No. ACC 441, Leibniz Institute DSMZ-German Collection
of Microorganisms and Cell Cultures, Braunschweig, Germany)
in RPMI 1,640 medium (Sigma-Aldrich) supplemented with 10%
heat-inactivated FBS (Life Technologies Corporation, Carlsbad,
CA, USA), 100 U/ml penicillin, 100µg/ml streptomycin (both
from Sigma-Aldrich) and 5% non-essential amino acids (Life
Technologies Corporation). For experiments, the GEN2.2 cells
were removed from the feeder layer and seeded on 24-well plates
at a concentration of 5× 105 cells/500µl in complete RPMI 1,640
medium (Sigma-Aldrich). Cell lines were grown and incubated at
37◦C in 5% CO2, at humidified atmosphere.
Isolation and Culturing of Primary Human
Cells
Human heparinized leukocyte-enriched buffy coats were
obtained from healthy blood donors drawn at the Regional
Blood Center of Hungarian National Blood Transfusion Service
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(Debrecen, Hungary) in accordance with the written approval of
the Director of the National Blood Transfusion Service and the
Regional and Institutional Ethics Committee of the University of
Debrecen, Faculty of Medicine (Debrecen, Hungary).
Peripheral blood mononuclear cells (PBMC) were separated
from buffy coats by Ficoll-Paque Plus (Amersham Biosciences,
Uppsala, Sweden) gradient centrifugation. Monocytes were
purified from PBMCs by positive selection using magnetic
cell separation with anti-CD14-conjugated microbeads
(Miltenyi Biotec, Bergish Gladbach, Germany) according to
the manufacturer’s instructions. Freshly isolated cells were
seeded in 24-well cell culture plates at a density of 1 × 106
cells/ml in RPMI 1,640 medium (Sigma-Aldrich) supplemented
with 10% heat-inactivated FBS, 2mM L-glutamine, 100 U/ml
penicillin, 100µg/ml streptomycin (all from Sigma-Aldrich),
80 ng/ml GM-CSF (Gentaur Molecular Products, London, UK),
and 50 ng/ml IL-4 (PeproTech, Brussels, Belgium) for 5 days. On
day 2, the half of the culture media was replaced with fresh media
and the same amounts of GM-CSF and IL-4 were added to the
cell cultures. Cells were used for experiments on day 5, when cells
display immature DC phenotype (DC-SIGN/CD209+, CD14−,
CD1a+).
Primary human pDCs were isolated from PBMCs by positive
selection using the human CD304 (BDCA-4/Neuropilin-1)
MicroBead Kit (Miltenyi Biotec) according to the manufacturer’s
instructions, then cultured in 96-well plates at a density
of 1 × 105 cells/200 µl in RPMI 1,640 medium (Sigma-
Aldrich) supplemented with 10% heat-inactivated FBS (Life
Technologies Corporation), 2mM L-glutamine, 100 U/ml
penicillin, 100µg/ml streptomycin (all from Sigma-Aldrich), and
50 ng/ml recombinant human IL-3 (PeproTech).
Allogeneic naïve CD8+ T cells were isolated fromPBMCusing
the human naïve CD8+ T cell isolation kit (Miltenyi Biotec)
according to the manufacturer’s instructions and were used for
co-culture experiments as described below.
Cell Stimulation
For TLR activation GEN2.2 cells and primary human pDCs
were treated with TLR9 agonist CpG-A (ODN 2216, 1µM;
Hycult Biotech, Uden, The Netherlands) for 12 h. To induce
RIG-I expression GEN2.2 cells and primary human pDCs
were pre-treated with low dose of CpG-A (0.25µM) for 16 h.
Thereafter the cells were washed, re-seeded in fresh, complete
RPMI 1,640 medium and stimulated with 5
′
ppp-dsRNA
(InvivoGen, San Diego, CA, USA), a specific agonist of RIG-I in
complex with the transfection reagent LyoVecTM (InvivoGen),
according to the manufacturer’s recommendations. Briefly,
25 µl of the 5
′
ppp-dsRNA-LyoVecTM complex containing
1µg/ml working concentration of the RIG-I ligand was
added to the cells for the indicated time periods in all
experiments. For moDCs, on day 5 of the differentiation
half of the culture medium was removed, replaced by fresh
FIGURE 1 | Plasmacytoid DCs display distinct RIG-I expression profile compared to moDCs. GEN2.2 cells (A,D) and primary human pDCs (B,E) were treated with
TLR9 agonist CpG-A (0.25µM) for 16 h then the protein level of RIG-I was determined by western blotting. (C,F) Freshly isolated monocytes were seeded in 24-well
plates and differentiated as described in the Materials and Methods. The protein level of RIG-I was measured by western blotting. Representative blots are shown in
(A–C). Data are shown as mean ± SD of at least three independent measurements in (D–F). *p < 0.05, **p < 0.01, ****p < 0.0001.
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medium then cells were exposed to 5
′
ppp-dsRNA-LyoVecTM
complexes for 12 h. In parallel experiments cells were treated
with indicated concentrations of the glycolysis inhibitor
2-deoxy-D-glucose (2-DG, Sigma-Aldrich) or OXPHOS
inhibitor carbonylcyanide m-chlorophenylhydrazone (CCCP,
Sigma-Aldrich).
Determination of Cell Viability
Cell viability was assessed by 7-aminoactinomycin D (7-AAD;
10µg/ml; Sigma–Aldrich) staining for 15 min immediately
before flow cytometric analysis. Fluorescence intensities were
measured with FACS Calibur cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA) and data were analyzed with FlowJo
software (TreeStar, Ashland, OR, USA).
Quantitative Real-Time PCR
Total RNA was isolated from 5 × 105 cells using Tri
reagent (Molecular Research Center, Inc., Cincinnati, OH,
USA). One microgram of total RNA was treated with DNase
I (Thermo Fisher Scientific, Waltham, MA, USA) to exclude
amplification of genomic DNA then reverse transcribed into
cDNA using the High Capacity cDNA RT Kit of Applied
Biosystems (Foster City, CA, USA). Gene expression assays were
purchased from Thermo Fisher Scientific for IFNB, hexokinase
2 (HK2), lactate dehydrogenase A (LDHA), hypoxia-inducible
factor 1-alpha (HIF1A), and from Integrated DNA Technologies
(Coralville, IA, USA) for IFNA1 and PPIA (cyclophilin A).
Quantitative PCR was performed using the ABI StepOne Real-
Time PCR System (Applied Biosystems) and cycle threshold
FIGURE 2 | Inhibition of glycolysis influences the viability and RIG-I expression of GEN2.2 cells in a concentration-dependent manner. (A,B) GEN2.2 cells were treated
with increasing concentration of 2-deoxy-D-glucose (2-DG; 1–50mM) then cell viability was analyzed by flow cytometry. (C,D) GEN2.2 cells were left untreated,
treated with TLR9 ligand CpG-A (0.25µM) alone or in combination with increasing concentrations of 2-DG (1–10mM) for 16 h then the protein level of RIG-I was
measured by western blot. (A) Representative dot plots are shown, where numbers indicate the percentage of 7-aminoactinomycin D (7-AAD) negative cells. (B) Bar
graphs show the mean ± SD of four independent experiments. (C) Representative blot is shown. (D) Bar graphs represent the mean ± SD of four individual
experiments. **p < 0.01, ***p < 0.001 ****p < 0.0001 vs. control; ##p < 0.01.
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FIGURE 3 | A shift to glycolysis is essential to the CpG-A-induced production of type I IFNs in GEN2.2 cells. (A,D) GEN2.2 cells were treated with 1µM of CpG-A,
and the expression of IFNA1 and IFNB was measured in a time-dependent manner at the mRNA level by Q-PCR. (B,C,E,F) GEN2.2 cells were left untreated, treated
(Continued)
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FIGURE 3 | with 1µM of CpG-A alone or in combination with increasing concentrations of 2-deoxy-D-glucose (2-DG; 1–10mM) for 12 h. The IFN-α and IFN-β
expression was assessed by real-time PCR at the mRNA level (B,E) and by ELISA at the protein level (C,F). (G) Following activation with CpG-A real-time ECAR of
GEN2.2 cells was determined by EFA. The results of a representative experiment are shown. (H) Lactate concentrations were measured from the supernatants at
12 h. The expression of LDHA (I), HK2 (J), and HIF1A (K) was assessed at the mRNA level by real-time PCR. Figures represent the mean ± SD of 4–6 independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, ND, not determined.
values were determined using the StepOne v2.1 Software
(Applied Biosystems). The relative amount of mRNA (2−1CT)
was obtained by normalizing to the PPIA (Integrated DNA
Technologies) housekeeping gene in each experiment.
Assessment of Cytokine Levels and Lactic
Acid From the Supernatants of Cell
Cultures
Cell culture supernatants were collected at the indicated time
points and IFN-α and IFN-β levels were measured by the
VeriKineTM Human Interferon Alpha and Beta ELISA kits,
respectively, (PBL Interferon Sources, Piscataway, NJ, USA)
according to the manufacturer’s instructions. Lactate production
of the cells was detected using the Glycolysis Cell-Based Assay
Kit (Cayman Chemical, Ann Arbor, Michigan, USA) according
to the manufacturer’s instructions. Absorbance measurements
were carried out by a Synergy HT microplate reader (Bio-
Tek Instruments, Winooski, VT, USA) at 450 nm for cytokine
detection and at 490 nm for lactate assay.
Real-Time Extracellular Flux Analysis
Human pDCs and moDCs were harvested, washed and
resuspended in Agilent Seahorse XF Base Medium (pH 7.4;
Agilent Technologies, Santa Clara, CA, USA) supplemented
with 10mM glucose, 2 mmol/L glutamine and 1% FBS and
seeded onto Cell-Tak (Corning Inc., NY, USA)-coated Seahorse
XF96 Cell Culture Microplates (Agilent Technologies) at a
density of 1.5 × 105 cells per well. Cells were incubated at
37◦C in a CO2-free incubator for 1 h before the experiments.
Extracellular acidification rate (ECAR) and oxygen consumption
rate (OCR) were measured simultaneously in real-time with
a Seahorse XF96e Extracellular Flux Analyzer (EFA; Agilent
Technologies). The compounds, CpG-A and 5′ppp-dsRNA were
added immediately before EFA measurements.
Detection of Mitochondrial Reactive
Oxygen Species (mtROS)
Primary pDCs and moDCs were loaded with 5µM MitoSoxTM
Red mitochondrial superoxide indicator (Life Technologies
Corporation) and incubated for 10min at 37◦C protected from
light. Then cells were washed gently three times with warm PBS
buffer (Sigma-Aldrich) to remove the excess fluorescent dye and
plated in 96-well black polystyrene plate at a density of 2 ×
105 cells/200 µl in RPMI 1,640 medium (Sigma-Aldrich). Cells
were then left untreated or stimulated with 5′ppp-dsRNA as
described above. Fluorescence intensity of MitoSox
TM
Red was
recorded at 580 nm by a Synergy HT microplate reader (Bio-Tek
Instruments).
Western Blotting
For western blotting 5 × 105 cells were lysed in Laemmli
buffer and then the protein extracts were resolved by SDS-
PAGE using 10% polyacrylamide gel and electro-transferred
to nitrocellulose membranes (Bio-Rad Laboratories GmbH,
Munich, Germany). Non-specific binding sites were blocked
with 5% non-fat dry milk diluted in TBS Tween buffer (50mM
Tris, 0.5M NaCl, 0.05% Tween-20, pH 7.4). Membranes were
probed with the anti-RIG-I (Cat. No. 4520, Cell Signaling,
Danvers, MA, USA) and anti-beta-actin (Cat. No. sc-47778,
Santa Cruz Biotechnology) primary antibodies. The bound
primary antibodies were labeled with anti-mouse or anti-rabbit
horseradish peroxidase-conjugated secondary antibodies (GE
Healthcare, Little Chalfont, Buckinghamshire, UK) at a dilution
of 1:5,000 and 1:10,000, respectively and were visualized by
the ECL system using SuperSignal West Pico chemiluminescent
substrate (Thermo Scientific, Rockford, IL, USA) and X-ray film
exposure. Densitometric analysis of immunoreactive bands was
performed using Image Studio Lite Software version 5.2 (LI-COR
Biosciences, Lincoln, Nebraska USA).
T Cell Proliferation Assay
Prior to co-culture with allogeneic naïve CD8+ T cells primary
human pDCs were stimulated with CpG-A (1µM) for TLR9
activation in the presence or absence of 2-DG for 6 h. In
parallel experiments, primary pDCs were pre-treated with CpG-
A (0.25µM) for 16 h to induce RIG-I expression as described
above then following thorough washing steps stimulated with
the specific RIG-I ligand 5′ppp-dsRNA with or without 2-DG
for 6 h. Immature moDCs were plated and stimulated with
5′ppp-dsRNA for 6 h in the presence or absence of glycolysis
inhibitor. Following incubation activated DCs were washed twice
with cell culture medium then co-cultured in 96-well U-bottom
plate with allogeneic naïve CD8+ T cells, which were previously
labeled with 0.5µM of carboxyfluorescein succinimidyl ester
(CFSE; Invitrogen, Carlsbad, CA, USA), for 5 days in the
presence of 1µg/ml anti-human CD3 monoclonal antibody (BD
Pharmingen) at a ratio of 1:10 (DC-T cell). After co-cultivation,
fluorescence intensities of CFSE dye were detected in the FL1
(530 ± 15 nm) channel on a BD FACS Calibur flow cytometer
(Becton Dickinson) and data were analyzed by FlowJo software
(Treestar).
Statistical Analysis
Multiple comparisons were performed using ANOVA, followed
by Bonferroni post-hoc test whereas two groups were compared
with Student’s unpaired t-test. Data analyses were performed
using GraphPad Prism v.6 software (GraphPad Software Inc., La
Jolla, CA, USA). Differences were considered to be statistically
significant at p< 0.05.
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FIGURE 4 | Glycolysis is not required to the RIG-I-mediated type I IFN production in GEN2.2 cells. (A,D) GEN2.2 cells were pre-treated with 0.25µM of CpG-A for
16 h then following thorough washing steps stimulated with the RIG-I agonist 5′ppp-dsRNA (RIGL, 1µg/ml) in a time-dependent manner. The mRNA level of
(Continued)
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FIGURE 4 | IFNA1 and IFNB was measured by Q-PCR. (B,C,E,F) After pre-treatment with low dose of CpG-A, GEN2.2 cells were exposed to 5′ppp-dsRNA in the
absence or presence of the indicated concentrations of 2-deoxy-D-glucose (2-DG; 1–10mM). The IFN-α and IFN-β expression was assessed by real-time PCR at the
mRNA level (B,E) and by ELISA at the protein level (C,F). (G) Following activation with 5
′
ppp-dsRNA real-time ECAR of GEN2.2 cells was determined by EFA. The
results of a representative experiment are shown. (H) Lactate levels were measured from the supernatants of the cell cultures. The expression of LDHA (I), HK2 (J),
and HIF1A (K) was assessed at the mRNA level by real-time PCR. Data represent the mean ± SD of at least three independent experiments. **p < 0.01, ***p <
0.001, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, ND, not determined.
RESULTS
Plasmacytoid DCs Display Distinct RIG-I
Expression Profile Compared to moDCs
Due to the limited number of pDCs in human peripheral blood
we performed most of our experiments on the human pDC
cell line GEN2.2 that shares similar phenotypic and functional
properties with primary human pDCs (22, 23). Furthermore,
our main findings have been validated in primary human pDCs
isolated from peripheral blood of healthy volunteers. Besides
we have used moDCs generated from human peripheral blood
monocytes in vitro as it serves as an ideal model for studying
DC functionality (24). First we investigated the expression profile
of RIG-I in these DC subtypes. Previously we have published
that GEN2.2 cells require a pre-treatment with TLR9 agonist
CpG-A to express the cytosolic RIG-I receptor (25, 26) as also
shown in Figures 1A,D of the present study. Similarly to GEN2.2
cells RIG-I is also absent from resting primary pDCs (8, 26)
but can be significantly upregulated upon exposure to CpG-
A (Figures 1B,E) showing a unique RIG-I expression profile
in pDCs. On the contrary, RIG-I was gradually upregulated
duringmoDC differentiation, and was constantly present in 5 day
immature moDCs (Figures 1C,F) (26). Therefore, these two DC
subtypes provide potential models to study the RIG-I-induced
metabolic changes in cell types with different RIG-I expression
profile, namely in moDCs that constitutively express RIG-I and
in pDCs with inducible RIG-I expression.
Inhibition of Glycolysis Influences the
Viability and RIG-I Expression of GEN2.2
Cells
Growing data support the idea that activation of DCs with
various TLR agonists is coupled with a metabolic transition
(17, 20). To investigate the role of glycolysis in pDC activation,
cells were treated with the potent glycolysis inhibitor 2-deoxy-D-
glucose (2-DG). First we titrated 2-DG to determine the optimal
concentration that would be tolerated by GEN2.2 cells. Our
results show that low doses of 2-DG (1–5mM) do not or only
slightly (10mM) affected cell viability, whereas higher doses
(20–50mM) were not tolerated by GEN2.2 cells (Figures 2A,B).
Based on our dose-response curve we have decided to use
1, 5, and 10mM of 2-DG to our further experiments which
concentrations of 2-DG did not markedly increase the ratio of
7-aminoactinomycinD (7-AAD) positive cells in the cell cultures.
Investigating the impact of glycolysis blockade on RIG-I
expression we found that 1 and 5mM concentrations of 2-DG
did not influence the CpG-A induced expression of RIG-I in
GEN2.2 cells, whereas 10mM of 2-DG decreased its protein
levels significantly (Figures 2C,D). These results indicate that the
RIG-I expression can be controlled by glycolysis in pDCs.
TLR but Not RLR Stimulation Requires a
Shift Toward Glycolysis to Induce a Robust
Type I IFN Production in GEN2.2 Cells
Previously we have described that following recognition of viral
nucleic acids the type I IFN production of pDCs occurs in
two waves (8). Endosomal TLRs mediate early type I IFN
production; whereas cytosolic RLRs induced by TLR stimulation
substantially contribute to the late phase of IFN responses. We
sought to test the role of glycolysis in both the first and second
phase of type I IFN responses in human pDCs. First we used
the TLR9 ligand CpG-A (1µM) to induce early type I IFN
production in GEN2.2 cells. Time-dependent analysis of IFNA1
and IFNB expression shows a peak at 12 h following CpG-A
stimulation (Figures 3A,D); therefore, we have studied the effect
of glycolysis at this time point. Inhibition of glycolysis by 2-DG
interrupted the CpG-A induced expression of IFN-α and IFN-β
in a dose-dependent manner both at the mRNA (Figures 3B,E)
and protein level (Figures 3C,F) indicating a critical role for
glycolysis in these processes. The glycolysis inhibitor applied
alone did not induce type I IFN production at any of the
used concentrations (data not shown); therefore we excluded
those treatment conditions from subsequent experiments. Next
we measured real-time ECAR, an indicator of glycolysis, and
found that GEN2.2 cells increased their ECAR levels following
CpG-A administration (Figure 3G). Consistent with this, the
elevated lactate production of CpG-A-stimulated cells indicates
an increase in glycolytic activity that could be inhibited by
administration of 2-DG (Figure 3H). We have also analyzed the
changes in the expression of key glycolytic genes in CpG-A-
exposed GEN2.2 cells at the mRNA level and we found that
LDHA, HK2, and HIF1A are significantly upregulated upon
exposure to CpG-A (Figures 3I–K). All these results indicate that
endosomal TLR9 stimulation requires glycolysis to induce type I
IFN secretion in GEN2.2 cells.
Next we asked whether pDC activation in response to RIG-
I stimulation is also accompanied by a shift toward glycolysis.
Therefore, GEN2.2 cells were pre-treated with low dose of CpG-
A (0.25µM) for 16 h to induce the cytosolic expression of
RIG-I then following thorough washing steps stimulated with
the specific RIG-I agonist 5′ppp-dsRNA. We have previously
developed and applied this method successfully to study RLR
responses in pDCs since a pre-treatment with low dose of CpG-
A does not result in cell exhaustion (8, 25). The activation of
pDCs with a RIG-I ligand causes a more rapid type I IFN
response than the activation with a TLR9 ligand. IFNA1 and
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FIGURE 5 | The type I IFN production of GEN2.2 cells induced by a second exposure to CpG-A also depends on glycolytic metabolism. GEN2.2 cells were
pre-treated with 0.25µM of CpG-A for 16 h then following thorough washing steps re-stimulated with 1µM CpG-A (re-CpG-A) in the absence or presence of
(Continued)
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FIGURE 5 | 2-deoxy-D-glucose (2-DG; 1–10mM). The IFNA1 and IFNB mRNA expression level was assessed by real-time PCR (A,C) and the IFN-α and IFN-β
protein level was measured by ELISA (B,D) at 12 h. (E) Lactate concentrations were determined from the supernatants of the cells at 12 h. The expression of LDHA
(F), HK2 (G), and HIF1A (H) was assessed at the mRNA level by real-time PCR. (A–H) Bar graphs represent the mean ± SD of four independent experiments. *p <
0.05, **p < 0.01, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, ND, not determined.
IFNB mRNA expression peaks at 1–3 h after RIG-I stimulation
thus we have studied the impact of glycolysis inhibition at
3 h (Figures 4A,D). Interestingly, disruption of glycolysis by 2-
DG significantly increased the 5′ppp-dsRNA-induced expression
of IFN-α and IFN-β both at the mRNA and protein level
(Figures 4B,C,E,F). Further we found that pDC activation in
response to 5′ppp-dsRNA was not accompanied by an increase
in ECAR (Figure 4G) in contrast to TLR9 activation. These
results were supported by the findings that RIG-I stimulation
did not give rise to elevated lactate production (Figure 4H) or
upregulation of glycolysis-associated genes (Figures 4I–K). All
these results imply that RIG-I-mediated type I IFN responses
do not depend on glycolysis and instead use other metabolic
pathways to ensure energy for the production of late type I IFN
secretion.
In parallel experiments after the pre-treatment with low dose
of CpG-A (0.25µM)we used high dose of CpG-A (1µM) instead
of RIG-I ligand as a second stimulus to exclude the possibility
that a preceding activation modifies the metabolic requirements
to a subsequent stimulus. Here we observed that re-stimulation
with CpG-A also requires glycolysis to induce IFN-α production
in GEN2.2 cells (Figure 5). Particularly, blockade of glycolysis by
2-DG dampened IFN-α and IFN-β expression both at the mRNA
(Figures 5A,C) and protein level following re-stimulation with
CpG-A (Figures 5B,D). Furthermore, a second stimulus with
CpG-A increased lactate production, which was inhibited by 2-
DG administration (Figure 5E), and upregulated LDHA, HK2,
and HIF1A mRNA levels significantly (Figures 5F–H). All these
results suggest that enhanced glycolysis dominates both early and
late TLR9 responses, whereas RIG-I-mediated signaling does not
rely on it in GEN2.2 cells.
TLR but Not RLR Stimulation Enhances
Glycolysis to Induce the Production of
Type I IFNs Even in Primary Human pDCs
To confirm our results we have also repeated our experiments
with primary human pDCs. Due to the limited cell number
only one concentration of 2-DG (5mM) was tested that did
not alter cell viability neither of GEN2.2 cells (Figures 2A,B)
nor of primary pDCs (Figures 6D,E,I,J). Our results are in line
with the data obtained by studies on the GEN2.2 cell line.
The CpG-A-induced IFN-α and IFN-β production of primary
pDCs was impaired in the presence of 2-DG (Figures 6A,B),
whereas RIG-I-mediated IFN-α and IFN-β secretion was rather
further increased in the presence of the glycolysis inhibitor
(Figures 6F,G). Further we observed elevated lactate production
in the supernatants of CpG-A stimulated cells that was reduced
when cells were co-treated with 2-DG (Figure 6C). On the
contrary, we did not observe any changes in the lactate levels
of RIG-I stimulated pDCs (Figure 6H) indicating that RIG-I
activation does not engage glycolysis and might use different
metabolic pathways to serve macromolecule/protein synthesis.
In order to further investigate the metabolic signature of
RIG-I stimulated GEN2.2 cells and primary pDCs we wanted
to study the importance of OXPHOS in RIG-I signaling.
Therefore, OXPHOS was uncoupled by the addition of
potent OXPHOS inhibitor carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) (Supplementary Figure 1). First we
determined the optimal concentrations (1 and 5µM) of CCCP
to treat GEN2.2 cells (Supplementary Figures 1A,B), then
observed that RIG-I-induced IFN-α and IFN-β production
of GEN2.2 cells was reduced in the presence of CCCP
(Supplementary Figures 1C–F). Performing real-time
measurements of OCR in pDCs we observed a minimal increase
in OCR upon RIG-I stimulation (Supplementary Figure 1G). In
primary human pDCs CCCP co-treatment also showed negative
impact on the RIG-I induced IFN-α and IFN-β secretion
(Supplementary Figures 2A,B) without influencing the viability
of the cells (Supplementary Figures 2C,D). Furthermore, we
detected elevated mtROS levels in GEN2.2 cells and primary
pDCs after RIG-I activation (Supplementary Figures 1H, 2E).
All these observations support the hypothesis that in contrast
with TLR9 activation, human pDCs activated via RIG-I do not
require glycolysis and might favor OXPHOS to produce type I
IFNs.
Glycolysis Is Essential to the RIG-I-Induced
Type I IFN Production of moDCs
In order to test whether these results are specific to human
pDCs we extended our studies on immature moDCs, which
constantly express RIG-I in their resting state. First we tested
the effects of 2-DG on the viability of moDCs. We have found
that in contrast to pDCs moDCs tolerate all applied doses of 2-
DG (1–50mM) (Figures 7A,B). For better comparison, to our
further experiments we used those 2-DG concentrations (1, 5,
and 10mM) which were also effective in pDCs.
In the next step we observed themaximal expression ofmRNA
for IFN-α and IFN-β at 12 h in response to RIG-I stimulation
(Figures 7C,F), therefore we have studied the effects of glycolysis
at this time point. Next we evaluated the impact of 2-DG on
the RIG-I-stimulated IFN-α and IFN-β expression at 12 h and
found that both the mRNA (Figures 7D,G) and protein levels
(Figures 7E,H) are dampened by the inhibition of glycolysis.
We also examined the metabolic profile of RIG-I stimulated
moDCs in real-time and found a rapid increase in ECAR
(Figure 7I) and decrease in OCR (Supplementary Figure 3G) in
contrast to pDCs (Figure 4G and Supplementary Figure 1G).
Lactate levels and the expression of key glycolytic genes
(LDHA, HK2, and HIF1A) were also elevated following RIG-
I stimulation of moDCs suggesting increased glycolytic activity
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FIGURE 6 | TLR9 but not RIG-I activation requires glycolysis to induce the production of type I IFNs in primary human pDCs. Freshly isolated primary human pDCs
were stimulated with 1µM of CpG-A in the absence or presence of 2-deoxy-D-glucose (2-DG; 5mM) then IFN-α and IFN-β protein levels (A,B) and lactate
(Continued)
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FIGURE 6 | concentrations (C) were measured from the supernatants of the cells at 12 h. In parallel experiments cells were pre-treated with low dose of CpG-A for
16 h then following thorough washing steps stimulated with 5′ppp-dsRNA (RIGL, 1µg/ml) alone or in combination with 5mM of 2-DG or left untreated. IFN-α and
IFN-β protein levels (F,G) and lactate concentrations (H) were measured from the supernatants at 6 h. (D,E,I,J) Cell viability was measured by 7-aminoactinomycin D
(7-AAD) staining using flow cytometry. (D,I) Representative dot plots are shown where numbers indicate the percentage of 7-AAD negative cells. (A–C,E,F–H,J) Data
represent the mean ± SD of three individual experiments. *p < 0.05, ***p < 0.001, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001, ND, not
determined.
(Figures 7J–M). On the contrary, moDCs were less sensitive
to CCCP treatment than pDCs (Supplementary Figures 3A,B).
Furthermore, co-treatment of moDCs with specific RIG-I ligand
and CCCP, did not alter significantly the type I IFN production
as compared to moDCs treated with RIG-I ligand alone
(Supplementary Figures 3C–F). Moreover, the RIG-I ligand-
exposed moDCs did not display increased mtROS production
(Supplementary Figure 3H). All these results indicate that in
contrast to pDCs, activation of moDCs via RIG-I results in a
metabolic switch from OXPHOS to glycolysis.
TLR9-Stimulated Primary Human pDCs
and RIG-I-Activated moDCs but Not
RIG-I-Stimulated pDCs Require Glycolytic
Metabolism to Induce Allogeneic Naïve T
Cell Proliferation
The transition of DCs from a quiescent into an activated state
requires metabolic changes that might also shape their capacity to
activate T cells (27). In the present study we have also investigated
the impact of metabolism on the capacity of human DCs to
interact with T cells. Therefore, highly purified allogeneic naïve
CD8+ T cells were co-cultured with primary human pDCs as
well as moDCs (Figure 8). Prior to co-culturing, pDCs were
stimulated with CpG-A or 5
′
ppp-dsRNA, and moDCs were also
exposed to RIG-I ligand in the presence or absence of 5mM2-DG
or left untreated for 6 h.
Our results show that pDCs treated with TLR9 ligand CpG-
A alone induce significant T cell proliferation which process
was inhibited when pDCs were activated in the presence
of 2-DG (Figures 8A,D). On the contrary, RIG-I-stimulated
pDCs induced substantial T cell proliferation which was not
influenced by 2-DG treatment of pDCs (Figures 8B,E). However,
activation of moDCs with specific RIG-I ligand 5
′
ppp-dsRNA
increased their T cell priming capacity which was significantly
impaired upon co-treatment with 2-DG (Figures 8C,F). These
observations suggest that the glycolysis in CpG-A-activated
pDCs and RIG-I-stimulated moDCs is essential to induce the
proliferation of CD8+ T cell whereas the T cell priming capacity
of RIG-I stimulated pDCs does not depend on it.
DISCUSSION
DCs are a heterogeneous family of cells that play an essential
role in detecting pathogens through a wide array of PRRs such
as TLRs and RLRs (28, 29). Ligation of these receptors leads
to DC activation characterized by profound changes in gene
expression allowing the production of inflammatory mediators
as well as the upregulation of costimulatory molecules and
major histocompatibility complex (MHC) I and II (30, 31). All
these newly acquired properties enable DCs to initiate local
inflammation and prime T cell responses (31). A growing
body of evidence indicates that stimulation of immune cells
including DCs is accompanied by metabolic reprogramming
that plays an integral role in their activation process (12, 32).
In particular, in response to TLR agonist cDCs and moDCs
switch from OXPHOS to glycolysis, the inhibition of which
impairs their activation and survival (17, 33, 34). Nevertheless,
divergent findings have been reported concerning the role of
cellular metabolism in endosomal TLR-mediated pDC activation
(18, 20). To our present knowledge, the plausible relation of
cellular metabolism to RLR signaling has not been addressed yet,
therefore, in this study, we focused on the metabolic profile of
RIG-I-stimulated human pDCs.
It has first been described in tumor cells that a metabolic
switch from OXPHOS to glycolysis occurs even under normoxic
condition to meet energy requirements for cell growth (35). The
phenomenon is known as the Warburg effect, which is assumed
to be utilized similarly by T-cells to promote proliferation and
differentiation into effector cells (36). In contrast, the adoption
of Warburg mechanism by innate immune cells, including
macrophages and DCs appears to support functional changes
such as the secretion of cytokines (12).
The importance of glycolysis in TLR-mediated DC activation
has first been recognized by Jantsch et al. (34). They have reported
that the TLR4-mediated activation of mouse bone marrow
(BM)-derived DCs is highly dependent on glycolysis which is
tightly controlled by HIF-1α. Another study demonstrated that
stimulation of mouse BM-derived DCs with TLR2, TLR4, and
TLR9 ligands promotes aerobe glycolysis that is accompanied
by a decrease in mitochondrial activity and OXPHOS (17).
Furthermore, it was found that the metabolic switch is supported
by the phosphatidylinositol 3-kinase (PI3K)/Akt signaling and
inhibited by the adenosine monophosphate-activated protein
kinase (AMPK), a regulator of OXPHOS and by the anti-
inflammatory cytokine IL-10. In subsequent studies it has been
revealed that the early TLR-driven glycolytic reprogramming
of BM-derived DCs are mediated via TANK-binding kinase
1 (TBK1), IκB kinase ε (IKKε), and Akt by promoting the
association of the glycolytic enzyme HK2 to the mitochondria
(27), whereas the long-term commitment to glycolysis is
regulated by the mammalian target of rapamycin complex 1
(mTORC1) that induces the expression of HIF1α and inducible
nitric oxide synthase (iNOS) (37). Furthermore, the authors
propose that the prolonged commitment to glycolysis is only
a survival mechanism of iNOS expressing DCs, in which NO
production inhibits the mitochondrial electron transport chain
(37). Nevertheless, an early increase in glycolytic flux, when iNOS
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FIGURE 7 | Glycolytic switch is required to the RIG-I-mediated type I IFN production in moDCs. (A,B) Immature moDCs were treated with increasing concentration of
2-deoxy-D-glucose (2-DG; 1–50mM) then cell viability was analyzed by flow cytometry. (C,F) Immature moDCs were stimulated with the RIG-I agonist 5′ppp-dsRNA
(Continued)
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FIGURE 7 | (RIGL, 1µg/ml) in a time-dependent manner. Kinetics expression of IFNA1 and IFNB mRNA was measured by Q-PCR. (D,E,G,H) In parallel experiments
moDCs were treated with RIG-I ligand in the absence or in the presence of the indicated concentrations of 2-deoxy-D-glucose (2-DG; 1–10mM) for 12 h. The IFN-α
and IFN-β expression was assessed by real-time PCR at the mRNA level (D,G) and by ELISA at the protein level (E,H). (I) Following activation with RIG-I agonist
5′ppp-dsRNA, real-time ECAR of moDCs was determined by EFA. The results of a representative experiment are shown. (J) Lactate concentrations were measured
from the supernatants at 12 h. The expression of LDHA (K), HK2 (L), and HIF1A (M) was assessed at the mRNA level by real-time PCR. (A) Representative dot plots
are shown where numbers indicate the percentage of 7-aminoactinomycin D (7-AAD) negative cells. (B–M) Data represent the mean ± SD of 4 independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ####p < 0.0001, ND, not determined.
is not active yet, has been suggested to be essential to initiate DC
activation in mice. This has been proven by the findings that 2-
DG, that inhibits HK2 in the glycolytic pathway, prevented the
TLR4-mediated maturation, cytokine, and lactate production of
mouse BM-derived DCs at early stages of activation (17, 27).
Furthermore, it has been suggested that the rapid increase in
glycolysis in TLR-activatedDCsmight serve the de novo synthesis
of fatty acids from citrate to support the expansion of organelles
required for cytokine/protein synthesis and secretion (27).
Similarly to mouse BM-derived DCs it has been shown
that human pDCs also switch to glycolysis to perform
antiviral functions (20). The exposure of human pDCs to
ssRNA viruses and gardiquimod increased HIF-1α protein
expression and induced early glycolysis, whereas decreased
OXPHOS activity. Moreover, blockade of glycolysis by 2-DG
impaired the TLR7-induced maturation and IFN-α secretion of
human pDCs indicating the critical role of glycolysis in pDC
antiviral responses. Another study demonstrated that under
pathological condition such as imiquimod-induced contact
dermatitis, stimulation of both human and murine pDCs with
imiquimod resulted in a decrease in OCR, and increase in
ECAR, however this was not the case with other TLR7/8 agonist,
such as gardiquimod or R848 (19). In this study, we show that
activation of human pDCs with the TLR9 agonist CpG-A also
leads to an increase in glycolysis as reflected by enhanced ECAR,
increased production of lactate and upregulation of glycolytic
genes. Moreover, TLR9-induced production of type I IFNs was
significantly inhibited by 2-DG highlighting the critical role for
glycolysis in the antiviral function of human pDCs. In contrast
to our findings, Wu et al. reported that TLR9-driven activation
of murine pDCs induced metabolic changes characterized by
increased OXPHOS and fatty acid oxidation that was found
to be dependent of type I IFNs (18). Furthermore, type I IFN
applied alone was also capable to enhance OXPHOS and fatty
acid oxidation in murine pDCs (18). Additionally, the authors
observed increased basal OCR in pDCs stimulated by imiquimod
and in BM-derived DCs activated with the TLR3/MDA5 ligand
polyinosinic-polycytidylic acid (polyI:C) (18). On the contrary, in
vivo stimulation of mouse DCs with polyI:C resulted inmetabolic
reprogramming toward aerobic glycolysis that has been found to
be regulated by type I IFNs (16).
So far, to our knowledge, only one study addressed the
connection between cellular metabolism and RLR-mediated
signaling (38). The authors used various cell lines (e.g.,
HEK293, MEF, J774A.1) transfected with plasmids encoding
RIG-I to their experiments and described that the RLR-mediated
antiviral response requires OXPHOS activity in response to
viral infection. In line with this finding, we observed that
pDC activation through RIG-I was not accompanied with an
increase in glycolysis. Furthermore, RIG-I-mediated production
of type I IFN was increased by 2-DG, whereas reduced by
CCCP, a chemical inhibitor of OXPHOS in human pDCs. Our
observations are consistent with the report of Yoshizumi et al.
showing that arresting OXPHOS activity by CCCP disrupts RLR-
mediated signaling in HEK293 cells (38). We also observed a
minimal increase in OCR upon RIG-I stimulation that further
support the idea that RIG-I-stimulated human pDCs rely on
OXPHOS to fulfill their function.
It is worth to mention that the low dose of CpG-A applied to
induce RIG-I in pDCs does not induce type I IFN production,
however can promote a shift toward glycolysis (data not shown).
Nevertheless, we suppose based on our results that this glycolytic
shift might be a transient change and pDCs can increase their
OXPHOS activity upon RIG-I stimulation.
Studies on human moDCs revealed that immature and
tolerogenic moDCs display metabolic signatures of OXPHOS,
fatty acid oxidation and glycolysis, whereas mature moDCs show
higher glycolytic rate mirrored by increased lactate production
(33). In contrast to murine mature BM-derived DCs, where the
switch leads to a total blockade of OXPHOS and thus shows
a complete dependence on glycolysis for energy production
and survival (37), mature human moDCs still display a limited
OXPHOS activity that is able to provide energy (33). In line
with our observations the authors found that 50mM 2-DG
resulted only in a slight decrease in cell viability indicating
high metabolic adaptation for survival. Interestingly, mature and
immature moDCs showed similar levels of iNOS expression
and NO production suggesting that the TLR-induced decrease
in mitochondrial activity is NO-independent in human moDCs
(33) in contrast to mouse DCs (37). We found that, in
contrast to pDCs, human moDCs stimulated via RIG-I increased
lactate release, upregulated the expression of glycolytic related
genes, and displayed higher ECAR and reduced OCR. While
CCCP treatment did not have any significant effects, blockade
of glycolysis by 2-DG impaired significantly the type I IFN
production of moDC indicating a dependence on glycolytic
metabolism rather than OXPHOS.
In addition, we observed remarkable differences between
primary pDCs and moDCs concerning their mtROS production
as RIG-I stimulation increased mtROS levels only in pDCs but
not in moDCs. Interestingly, blockade of glycolysis increased the
RIG-I-triggered type I IFN secretion in pDCs, whereas decreased
it in moDCs. These results imply that, in contrast to moDCs,
the defect of glycolysis in pDCs promotes OXPHOS activity
that can result in increased mtROS production. Previously
we have described that elevated levels of mtROS support the
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FIGURE 8 | TLR9-stimulated primary human pDCs and RIG-I-activated moDCs but not RIG-I-activated pDC require glycolytic metabolism to induce allogeneic naïve
T cell proliferation. (A–F) CFSE-labeled allogeneic naïve CD8+ T cells were co-cultured with pDCs or moDCs pre-treated with the indicated reagents. After 5 days of
co-cultivation, cell division was measured by flow cytometry. (A–C) Representative histograms are shown where numbers indicate the percentage of viable dividing
CD8+ T cells. (D–F) Bar graphs represent the mean ± SD of four independent experiments. ***p < 0.001, ****p < 0.0001 vs. control; ###p < 0.001, ####p <
0.0001, 2-DG: 2-deoxy-D-glucose; ND, not determined, RIGL, RIG-I ligand.
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RIG-I-mediated responses in pDCs (25), thus we hypothesize
that this might be the reason behind the increased type I IFN
production of pDCs co-treated with RIG-I ligand and glycolysis
inhibitor.
So far, limited data are available concerning the impact of
metabolism on the capacity of human DCs to interact with T
cells. It has been reported that in vivo activation of murine DCs
in the presence of 2-DG impaired their CD4+ and CD8+ T
cell stimulatory capacity demonstrating a crucial role for TLR-
induced glycolysis in the priming functions of DCs (27).
Our data also suggest an essential role for glycolytic
metabolism in the priming function of TLR9-activated human
pDCs and RIG-I-stimulated moDCs. Interestingly, treatment of
pDCs with 2-DG did not have any effect on the allogeneic CD8+
T cell priming capacity of RIG-I-stimulated pDCs. All these data
suggest that the immunogenic capacity of different DC subtypes
coincides with their divergent metabolic demands.
In conclusion we show that different DC subtypes such as
human pDCs and moDCs have distinct metabolic requirements.
In response to RIG-I stimulation moDCs switch to glycolysis
whereas pDCs seems to rely on OXPHOS rather than glycolysis.
These differences might be explained by the fact that these
two DC subtypes possess different viral sensor repertoire which
elicit divergent antiviral responses. Plasmacytoid DCs apply
endosomal TLRs in the early phases of virus infection and
use RIG-I only in the later stages of antiviral responses. On
the contrary, moDCs engage both TLRs and RLRs during
the initial viral encounter which, as we suppose, requires a
switch to glycolysis to expand endoplasmic reticulum and
Golgi for the large-scale production of antiviral proteins (27).
Furthermore, our data imply that cellular metabolism controls
the T cell priming function of human DCs indicating that
metabolic manipulation of DCs might be used to modulate
their immune-polarizing properties as well. Overall, altering
human DC functionality through metabolic modulation requires
a more comprehensive knowledge and understanding due to
the complexity and diversity of antiviral responses induced by
various PRRs.
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